Quarterly report · Q2
8086.TEDINET S100PL3A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥260.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥242.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥6.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥12.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥12.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥8.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.01T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥888.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥768.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥237.2bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥190.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥95.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥25.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥41.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥23.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.34 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.99 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.78 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.54 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥33.97 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.65 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥340m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥168m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥18.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥18.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥15.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥203.9bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥200.8bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥44.9bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥34.1bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.8bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥849m |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥28.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥25.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥276.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥260.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥16.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥278.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥260.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥21.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥295m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥988m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥205m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥17.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥17.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥11.7bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥186.8bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥183.4bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥26.5bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥23.4bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥258.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥241.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥24.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥259.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥242.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥17.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥24.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 643
| Item | Context | Value | Unit |
|---|---|---|---|
| Exporting notes receivable discounted | CurrentQuarterInstant | － | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 11281000000 | JPY |
| Payroll and allowances sga | CurrentYTDDuration | 12631000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 7790000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 8445000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 3057000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 2907000000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 94000000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 3000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 369000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 381000000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 35000000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 35000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | Prior1YTDDuration | 8000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | CurrentYTDDuration | 5000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 80000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 711000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 183437000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember | 34972000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember | 23415000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 241824000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 295000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 242120000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 242120000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 3336000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember | 10182000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember | 3081000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 16600000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 988000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 17588000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -17588000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 186773000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember | 45154000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember | 26496000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 258424000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1284000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 259708000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -17588000000 | JPY |
| Net sales | Prior1YTDDuration | 242120000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 19593000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02688-000MedicineRelatedReportableSegmentsMember | 2606000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02688-000PharmaPackagingReportableSegmentMember | 2110000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 24310000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 205000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 24515000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -11652000000 | JPY |
| Operating income | Prior1YTDDuration | 12863000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 200823000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |